Biogen to halt late-stage trial of Alzheimer’s dug – Alzheimer’s Society comment
US pharmaceuticals company Biogen and its Japanese partner Eisai have announced they will discontinue a global Phase 3 trial for a promising Alzheimer’s disease treatment, aducanumab.
The decision comes after a “futility analysis” indicated the trials were unlikely to succeed.
Fiona Carragher, Chief Policy and Research Officer at Alzheimer’s Society, says:
'The halting of Biogen’s aducanumab is sad and unexpected news, but for the 850,000 people living with dementia in the UK today, we mustn’t lose hope, or sight, of the bigger picture.
'Dementia is a vastly complex condition, which presents a huge challenge to researchers.
'The lessons learnt from this amyloid targeting drug will inform future trials, taking us ever closer to a cure.
'With no new drugs for over 15 years initiatives such as the UK Dementia Research Institute and the Alzheimer’s Society’s Drug Discovery programme are leading the field in identifying new treatments, that could one day slow down or stop the progression of this heart-breaking condition.
'Research will beat dementia, but we urgently need more funding to make this a reality.'